Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration
- 1 November 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 11 (10) , 813-820
- https://doi.org/10.1097/00001813-200011000-00004
Abstract
The objective of this study was to compare the quantitative excretion of paclitaxel and metabolites after i.v. and oral drug administration. Four patients received 300 mg/m2 paclitaxel orally 30 min after 15 mg/kg oral cyclosporin A, co-administered to enhance the uptake of paclitaxel. Three weeks later these and three other patients received 175 mg/m2 paclitaxel by i.v. infusion. Blood samples, urine and feces were collected up to 48-96 h after administration, and analyzed for paclitaxel and metabolites. The area under the plasma concentration-time curve of paclitaxel after i.v. administration (175 mg/m2) was 16.2±1.7 μM·h and after oral administration (300 mg/m2) 3.8±1.5 μM·h. Following i.v. infusion of paclitaxel, total fecal excretion was 56±25%, with the metabolite 6α-hydroxypaclitaxel being the main excretory product (37±18%). After oral administration of paclitaxel, total fecal excretion was 76±21%, of which paclitaxel accounted for 61±14%. In conclusion, after i.v. administration of paclitaxel, excretion occurs mainly in the feces with the metabolites as the major excretory products. Orally administered paclitaxel is also mainly excreted in feces but with the parent drug in highest amounts. We assume that this high amount of parent drug is due to incomplete absorption of orally administered paclitaxel from the gastrointestinal tract.Keywords
This publication has 18 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of Oral PaclitaxelJournal of Clinical Oncology, 2000
- Co-administration of cyclosporin enables oral therapy with paclitaxelThe Lancet, 1998
- Experience With New Chemotherapeutic Agents in Non-small Cell Lung CancerChest, 1998
- Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestineProceedings of the National Academy of Sciences, 1997
- Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human fecesCancer Chemotherapy and Pharmacology, 1995
- Limited Sampling Strategies for Investigating Paclitaxel Pharmacokinetics in Patients Receiving 175 mg/m2 as a 3-Hour InfusionClinical Drug Investigation, 1995
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6?-hydroxytaxolCancer Chemotherapy and Pharmacology, 1995
- Isolation, Structural Determination, and Biological Activity of 6.alpha.-Hydroxytaxol, the Principal Human Metabolite of TaxolJournal of Medicinal Chemistry, 1994